A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy-Reference-Cited by-同舟云学术

A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy

Published:2010-08-12 Issue:6 Volume:67 Page:1265-1272
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Kato Ken,Tahara Makoto,Hironaka Shuichi,Muro Kei,Takiuchi Hiroya,Hamamoto Yasuo,Imamoto Haruhiko,Amano Norihito,Seriu Taku

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-010-1422-x.pdf

Reference28 articles.

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43–66

2. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108

3. Blot WJ, McLaughlin JK (1999) The changing epidemiology of esophageal cancer. Semin Oncol 26:2–8

4. Devesa SS, Blot WJ, Fraumeni JF Jr (1998) Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83:2049–2053

5. Vizcaino AP, Moreno V, Lambert R, Parkin DM (2002) Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1995. Int J Cancer 99:860–868

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of taxanes after PD-1 blockade exposure in advanced esophageal squamous cell carcinoma;Esophagus;2024-09-02

2. Definitive chemoradiotherapy with paclitaxel for locally advanced esophageal squamous cell carcinoma in older patients (PARADISE-1): a phase I trial;BMC Cancer;2024-07-19

3. 5-Fluorouracil plus L-leucovorin and oxaliplatin treatment for esophageal squamous cell carcinoma: A multicenter retrospective study;2024-06-11

4. Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma;Expert Opinion on Biological Therapy;2024-06-02

5. Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation;Expert Opinion on Drug Safety;2024-05